AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study.

Abstract

From March 1993 to October 1993, 20 consecutive, newly diagnosed acute promyelocytic leukemia (APL) patients from 13 Italian institutions entered in a pilot study named AIDA, combining all-trans retinoic acid (ATRA) with idarubicin (IDA). ATRA was administered orally beginning on the first day of induction at the dosage of 45 mg/m2/d until complete… (More)

Topics

5 Figures and Tables

Cite this paper

@article{Avvisati1996AIDAR, title={AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study.}, author={Giuseppe Avvisati and Francesco Lo Coco and Daniela Diverio and Michele Falda and F. Ferrara and Marco Lazzarino and Danilo Russo and Maria Concetta Petti and Franco Mandelli}, journal={Blood}, year={1996}, volume={88 4}, pages={1390-8} }